13. Serious adverse events: number of trials, participants, and relative effects for all class comparisons.
Treatment class comparison | Number of trials | N | Fixed effect‐fixed class effect model | Random effects‐fixed class effect (uniform prior) | Random effects‐fixed class effect (empirical prior) | |||
OR | 95% CrI | OR | 95% CrI | OR | 95% CrI | |||
Macrolide vs placebo | 8 | 1930 | 0.76 | 0.62 to 0.93 | 0.72 | 0.38 to 1.14 | 0.73 | 0.45 to 1.07 |
Quinolone vs placebo | 1 | 1149 | 1.00 | 0.72 to 1.34 | 1.21 | 0.29 to 3.24 | 1.08 | 0.42 to 2.27 |
Macrolide + tetracycline vs placebo | 1 | 195 | 0.97 | 0.52 to 1.66 | 1.12 | 0.27 to 2.84 | 1.00 | 0.36 to 2.19 |
Quinolone vs macrolide | 0 | 0 | 1.32 | 0.90 to 1.89 | 1.88 | 0.41 to 5.67 | 1.56 | 0.55 to 3.62 |
Macrolide + tetracycline vs macrolide | 1 | 198 | 1.28 | 0.68 to 2.19 | 1.67 | 0.42 to 4.31 | 1.41 | 0.52 to 3.15 |
Macrolide + tetracycline vs quinolone | 0 | 0 | 1.00 | 0.49 to 1.82 | 1.72 | 0.17 to 4.67 | 1.13 | 0.26 to 3.11 |
Abbreviations
CrI: credible interval; OR: odds ratio.